XERS Xeris Pharmaceuticals Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: XERS
  4. Earnings
?
Relative Growth: Rel. Growth: 89
Relative Strength: Rel. Strength: 41
Relative Valuation: Rel. Valuation: 44
Relative Profitability: Rel. Profitability: 96

EPS in 2026 (TTM): $0.07

Last Report Period Date: Mar 31, 2026

Based on the company's latest reports for March 2026, the EPS for the trailing twelve months is $0.07. Xeris Pharmaceuticals's earnings per share in 2025 amounted to $0, marking an increase from -$0.37 in 2024. During the quarterly period ending on Mar 31, 2026, XERS's earnings per share stood at $0.01.

XERS earnings history

Historical annual and quarterly earnings per share (EPS) data for Xeris Pharmaceuticals
EPS (TTM)
$0.07
EPS Growth YoY (Quarterly)
116.7%
EPS (Quarterly)
$0.01
EPS Growth (Quarterly)
-85.7%

Xeris Pharmaceuticals had an yealy EPS of $0, indicating an increase of 100% from -$0.37 recorded in 2024. The quarterly per-share earnings for the period ending Mar 31, 2026, was $0.01, indicating a 116.7% increase compared to the same quarter last year. XERS's 12-month EPS is $0.07 as of March 2026. Xeris Pharmaceuticals's annual EPS in 2024 was -$0.37, a 17.8% rise year-over-year.

XERS earnings chart

XERS EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
116.7%
EPS growth YoY
100%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

Xeris Pharmaceuticals has registered a growth in earnings per share of 116.7% over the past 12 months (YoY, quarterly).

XERS Earnings Waterfall

Breakdown of revenue, profit and net income for Xeris Pharmaceuticals

XERS Earnings vs Peers

What are the earnings of XERS compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
VIVS VivoSim Labs Inc. 0.77 91.2% N/A N/A
ORMP Oramed Pharmaceuticals Inc 1.44 418.8% N/A N/A
OMER Omeros Corp 7.88 98.1% N/A N/A
XERS Xeris Pharmaceuticals Inc 87.79 100% N/A N/A
OLMA Olema Pharmaceuticals Inc N/A 15% N/A N/A
ORIC Oric Pharmaceuticals Inc N/A 19.7% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.